Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.58 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402227 | 0.79 | HTT (0.88) | HTTFGFR1POLB | |
| SCHEMBL3419279 | 0.79 | HTT (0.88) | HTTFGFR1POLB | |
| SCHEMBL13052913 | 0.77 | HTT (0.77) | HTTFGFR1POLB | |
| Benzene SCHEMBL14876970 | 0.77 | HTT (1.00) | HTTFGFR1 | |
| SCHEMBL157265 | 0.77 | HTT (1.00) | HTTFGFR1 | |
| SCHEMBL12628749 | 0.77 | HCAR1 (0.49) | FGFR1HCAR1POLB | |
| Iodide SCHEMBL30645138 | 0.76 | HTT (0.96) | HTTFGFR1 | |
| SCHEMBL467858 | 0.76 | HTT (0.96) | HTTFGFR1 | |
| SCHEMBL4891428 | 0.76 | HTT (0.96) | HTTFGFR1 | |
| SCHEMBL27724758 | 0.76 | HTT (0.96) | HTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
| EP-2872502-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| EP-2858983-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB Biopharma SPRL (BE) | 2015-04-15 | — | — | EP | disclosed |
| WO-2014009302-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013186229-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB PHARMA S.A. (BE) | 2013-12-19 | — | — | WO | disclosed |
| EP-1517897-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000817-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | HTT 1177/4885FGFR1 4150/4885HCAR1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.